September 26, 2024 Non Regulatory LIDDS has decided to concentrate its activities on three project areas
February 27, 2024 Regulatory Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 27 February 2024
January 9, 2024 Regulatory Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 9 January 2024
December 4, 2023 Non Regulatory Nomination Committee appointed for the Annual General Meeting 2024 in LIDDS
July 7, 2023 Non Regulatory Interview with LIDDS’s Chairman of the Board published on the company’s website
July 6, 2023 Regulatory LIDDS announces closure of R&D project with Johnson & Johnson Enterprise Innovation Inc.
June 27, 2023 Regulatory LIDDS announces Cost Containment Measures to maximise the runway to reach a License Agreement
May 2, 2023 Non Regulatory LIDDS participates in LSX World Congress and ERLIG Therapeutic Oligo meetings
March 14, 2023 Non Regulatory LIDDS participates in BIO-Europe Spring and EACR Immuno-Oncology Meetings
February 20, 2023 Regulatory LIDDS’ rights issue is registered and trading in Paid Subscribed Shares ceases
February 7, 2023 Regulatory Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue
January 23, 2023 Non Regulatory The subscription period in LIDDS’ rights issue is starting today and the CEO has participated in an interview with Erik Penser Bank
January 9, 2023 Regulatory Bulletin from the Extraordinary General Meeting in LIDDS AB (publ) on the 9 January 2023
January 9, 2023 Non Regulatory LIDDS signs a deal with Alira Health on sell-side support in Licensing
December 8, 2022 Non Regulatory LIDDS presents at high-profile event in connection with Nobel Prize festivities
November 30, 2022 Non Regulatory Nomination Committee appointed for the Annual General Meeting 2023 in LIDDS
November 4, 2022 Non Regulatory Interview with LIDDS’ CEO Anders Månsson published on the company’s website
July 8, 2022 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in Israel
June 7, 2022 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in Japan and South Korea
February 24, 2022 Regulatory Complement to press release: Notice of Extraordinary General Meeting of LIDDS AB (publ)
February 22, 2022 Regulatory LIDDS secures financing of up to 40.8 MSEK to create foundation for new partnerships based on the NanoZolid® technology
February 17, 2022 Non Regulatory Invitation to LIDDS Capital Markets Day and presentation of new strategy and vision
December 29, 2021 Non Regulatory LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
December 20, 2021 Non Regulatory LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
December 17, 2021 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in China
November 17, 2021 Non Regulatory Nomination Committee appointed for the Annual General Meeting 2022 in LIDDS
November 15, 2021 Regulatory LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
October 4, 2021 Regulatory NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
September 28, 2021 Non Regulatory LIDDS patent covering the NanoZolid® production process granted in Russia and Australia
June 2, 2021 Regulatory LIDDS carry out a directed share issue of and is provided with approximately MSEK 45
June 1, 2021 Regulatory LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer
May 28, 2021 Non Regulatory LIDDS new CEO will present at Redeye’s Growth Day and Aktiespararna’s Småbolagsdagarna
April 16, 2021 Non Regulatory Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®
April 8, 2021 Non Regulatory International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules
March 2, 2021 Regulatory LIDDS enters R&D agreement with potential exclusive, global product license option
February 24, 2021 Non Regulatory LIDDS files patent application for method to treat brain cancer with intratumoral depot injections
February 4, 2021 Non Regulatory European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
December 22, 2020 Non Regulatory LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021
December 18, 2020 Non Regulatory Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot
November 18, 2020 Non Regulatory A review article defines LIDDS as a key player in TLR9 agonist research field and being the only provider having a sustained release product in development
October 26, 2020 Regulatory LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect
October 19, 2020 Non Regulatory LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020
August 20, 2020 Regulatory LIDDS licensee, Puheng Pharma, evaluates a novel expeditated regulatory path for Liproca Depot in China
June 11, 2020 Regulatory LIDDS announces a capital raise of a total of approximately SEK 59.3 million and accordingly secures long-term financing
May 19, 2020 Regulatory Correction of press release: Liproca Phase IIb study results indicate cancer control
May 18, 2020 Regulatory LIDDS announces positive meeting with the Swedish Medical Products Agency, confirming the Liproca® Depot Phase III study design
March 25, 2020 Regulatory LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project
February 11, 2020 Regulatory LIDDS: Last patient treated in Liproca® Depot open label extension study
January 14, 2020 Non Regulatory LIDDS: The United States Patent and Trademark Office has registered the LIDDS trademark NANOZOLID in the US
January 13, 2020 Non Regulatory LIDDS: Stockpicker´s buy recommendation for 2020 picks LIDDS share as one of twelve attractive Swedish companies
January 9, 2020 Regulatory LIDDS obtains novel US product patent that significantly broadens protection on NanoZolid® pharmaceuticals
December 10, 2019 Non Regulatory LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
December 2, 2019 Non Regulatory LIDDS Interview with the LPC-004 study investigator, Professor Laurence Klotz, about the LIDDS Liproca® Depot Phase IIb study results
November 16, 2019 Regulatory LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
November 7, 2019 Regulatory LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China
October 23, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year
September 24, 2019 Non Regulatory LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
September 24, 2019 Regulatory Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect
August 28, 2019 Non Regulatory LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019
May 6, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals
May 2, 2019 Regulatory LIDDS develops its own proprietary product for intratumoral immunotherapy – Freedom to operate analysis done for the TLR9-agonist project
April 2, 2019 Regulatory LIDDS announces a novel TLR9 agonist project and plan for Phase I clinical trial
March 18, 2019 Regulatory LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020
March 13, 2019 Non Regulatory LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study
March 6, 2019 Non Regulatory LIDDS: Final patient enrolled in Phase IIb Liproca® Depot prostate cancer study
February 5, 2019 Non Regulatory LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial
February 4, 2019 Non Regulatory LIDDS research activities in intratumoral immunotherapy are in line with leading oncology expert recommendations
November 21, 2018 Regulatory LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study
November 16, 2018 Non Regulatory LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
November 1, 2018 Non Regulatory LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
July 30, 2018 Regulatory New STING study opens up multi-billion dollar cancer immunotherapy market for LIDDS unique NanoZolid® technology
June 25, 2018 Non Regulatory LIDDS’ NanoZolid® technology recognized through publication of scientific article in Journal of Drug Delivery Science and Technolog
June 7, 2018 Regulatory LIDDS: Major European Investment Funds invest 21,7 MSEK in a direct share issue
May 16, 2018 Regulatory LIDDS signs license agreement for prostate cancer drug Liproca® Depot with major Chinese pharma company
May 15, 2018 Regulatory LIDDS broadens the scope of its technology platform by verifying NanoZolid® as subcutaneous depot for systemic delivery
March 15, 2018 Regulatory LIDDS: NanoZolid® with cutting edge STING agonist becomes a key project for LIDDS in immuno-oncology field
February 8, 2018 Regulatory LIDDS: Liproca® Depot effects on prostate cancer to be presented at the Paris Symposium for Magnetic Resonance in Medicine
January 10, 2018 Regulatory LIDDS: NanoZolid® with immune-stimulating agent confirms efficacy in an additional cancer model
December 27, 2017 Regulatory LIDDS: NanoZolid® with immune-stimulating agent demonstrates significant efficacy
July 20, 2017 Regulatory LIDDS: LIDDS and Recipharm establish industrial manufacturing capabilities for a novel prostate cancer product
March 28, 2017 Regulatory LIDDS patenting pharmaceutical products with large biomolecules in NanoZolid® for immunotherapy
January 23, 2017 Regulatory LIDDS: Clear effects for local tumour treatment of lung cancer – promising preclinical results with NanoZolid® and cytostatics are to be published